The "Twincretin" era for treating patients with type 2 diabetes has begun, with the US Food and Drug Administration's (FDA's) approval of tirzepatide for this indication on May 13, making it the first approved agent that works as a dual agonist for the two principal human incretins.
Tirzepatide represents "an important advance in the treatment of type 2 diabetes," said the FDA's Patrick Archdeacon, MD, associate director of the Division of Diabetes, Lipid Disorders, and Obesity, in a statement released by the agency.
